Oncotarget

Vol 3, No 12

December

View Archive »

Order a Reprint

About The Cover

GRP-R and FAK expressions correlate to neuroblastoma malignancy and GRP-induced FAK activation. More intense immunofluorescence of FAK and GRP-R were observed in BE(2)-C cells when compared to SK-N-SH cells. The figure of BE(2)-C was digitally enhanced for the cover of Oncotarget. See Lee et al.

Table of Contents

Editorial

The promise of dual targeting Akt/mTOR signaling in lethal prostate cancer

The promise of dual targeting Akt/mTOR signaling in lethal prostate cancer

https://doi.org/10.18632/oncotarget.771

Nicolas Floc'h,  and Cory Abate-Shen
1483-1484
PDF  |  HTML  |  Order a Reprint

PI3Kβ downstream of GPCRs – crucial partners in oncogenesis

PI3Kβ downstream of GPCRs – crucial partners in oncogenesis

https://doi.org/10.18632/oncotarget.787

Hashem A Dbouk, Oscar Vadas, Roger L Williams,  and Jonathan M Backer
1485-1486
PDF  |  HTML  |  Order a Reprint

Endotrophin – Linking Obesity with Aggressive Tumor Growth

Endotrophin – Linking Obesity with Aggressive Tumor Growth

https://doi.org/10.18632/oncotarget.796

Jiyoung Park,  and Philipp E. Scherer
1487-1488
PDF  |  HTML  |  Order a Reprint

Attacking MALT1 for ABC-DLBCL therapy

Attacking MALT1 for ABC-DLBCL therapy

https://doi.org/10.18632/oncotarget.794

Daniel Krappmann
1489-1490
PDF  |  HTML  |  Order a Reprint

mTOR inhibitor efficacy is determined by the eIF4E/4E-BP ratio

mTOR inhibitor efficacy is determined by the eIF4E/4E-BP ratio

https://doi.org/10.18632/oncotarget.799

Tommy Alain, Nahum Sonenberg,  and Ivan Topisirovic
1491-1492
PDF  |  HTML  |  Order a Reprint

Targeting Lymphomas Through MALT1 Inhibition

Targeting Lymphomas Through MALT1 Inhibition

https://doi.org/10.18632/oncotarget.819

Lorena Fontan,  and Ari Melnick
1493-1494
PDF  |  HTML  |  Order a Reprint

PU.1 is a tumor suppressor for B cell malignancies

PU.1 is a tumor suppressor for B cell malignancies

https://doi.org/10.18632/oncotarget.800

Yutaka Okuno,  and Hiromichi Yuki
1495-1496
PDF  |  HTML  |  Order a Reprint

Tumor-infiltrating macrophages, cancer stem cells and therapeutic responses

Tumor-infiltrating macrophages, cancer stem cells and therapeutic responses

https://doi.org/10.18632/oncotarget.792

Roheena Z Panni, David C Linehan,  and David G DeNardo
1497-1498
PDF  |  HTML  |  Order a Reprint

Coordinate PI3K pathway and Bcl-2 family disruption in AML

Coordinate PI3K pathway and Bcl-2 family disruption in AML

https://doi.org/10.18632/oncotarget.809

Prithviraj Bose, Mohamed Rahmani,  and Steven Grant
1499-1500
PDF  |  HTML  |  Order a Reprint

Targeting Tumor Stroma: Exploiting Apoptotic Priming

Targeting Tumor Stroma: Exploiting Apoptotic Priming

https://doi.org/10.18632/oncotarget.830

Joachim C. Mertens,  and and Gregory J. Gores
1501-1502
PDF  |  HTML  |  Order a Reprint

Commentaries

The Maintenance of Epigenetic States by p53: The Guardian of the Epigenome

The Maintenance of Epigenetic States by p53: The Guardian of the Epigenome

https://doi.org/10.18632/oncotarget.780

Arnold J. Levine,  and Benjamin Greenbaum
1503-1504
PDF  |  HTML  |  Order a Reprint

Reviews

Advances in Targeting Signal Transduction Pathways.

Advances in Targeting Signal Transduction Pathways.

https://doi.org/10.18632/oncotarget.802

James Andrew McCubrey, Linda S Steelman, William H Chappell, Lin Sun, Nicole M Davis, Stephen L Abrams, Richard A Franklin, Lucio Cocco, Camilla Evangelisti, Francesca Chiarini, Alberto M Martelli, Massimo Libra, Saverio Candido, Grazia Malaponte, Maria C Mazzarino, Paolo Fagone, Marco Donia, Ferdinando Nicoletti, Jerry Polesel, Renato Talamini, Jorg Basecke, Sanja Mijatovic, Danijela Maksimovic-Ivanic, Michele Milella, Agostino Tafuri, Joanna Dulińska-Litewka, Piotr Laidler, Antonio B D'Assoro, Lyudmyla Drobot, Kazuo Umezawa, Giuseppe Montalto, Melchiorre Cervello,  and Zoya N Demidenko
1505-1521
Abstract  |  PDF  |  HTML  |  Order a Reprint

Recent progress in genetics of aging, senescence and longevity: focusing on cancer-related genes

Recent progress in genetics of aging, senescence and longevity: focusing on cancer-related genes

https://doi.org/10.18632/oncotarget.889

Albert E. Berman, Olga V. Leontieva, Venkatesh Natarajan, James A. McCubrey, Zoya N. Demidenko,  and Mikhail A. Nikiforov
1522-1532
Abstract  |  PDF  |  HTML  |  Order a Reprint

Research Papers

Identification and Characterization of a Novel Chemotype MEK Inhibitor Able to Alter the Phosphorylation State of MEK1/2

Identification and Characterization of a Novel Chemotype MEK Inhibitor Able to Alter the Phosphorylation State of MEK1/2

https://doi.org/10.18632/oncotarget.747

Takayuki Yoshida, Junya Kakegawa, Takayuki Yamaguchi, Yoshiji Hantani, Nobuyuki Okajima, Toshiyuki Sakai, Yoshihiro Watanabe,  and Motonao Nakamura
1533-1545
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

Down-regulation of Sox7 is associated with aberrant activation of Wnt/β-catenin signaling in endometrial cancer

Down-regulation of Sox7 is associated with aberrant activation of Wnt/β-catenin signaling in endometrial cancer

https://doi.org/10.18632/oncotarget.667

David W Chan, Celia SL Mak, Thomas HY Leung, Karen KL Chan,  and Hextan YS Ngan
1546-1556
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to Ponatinib

All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to Ponatinib

https://doi.org/10.18632/oncotarget.692

Ophelie Cassuto, Maeva Dufies, Arnaud Jacquel, Alexandre Puissant, Clemence Ginet, Amine Hamouda, Frederic Luciano, Guillaume Robert, Jean-Michel Karsenti, Laurence Legros, Jill Patrice Cassuto, Pascal Lenain,  and Patrick Auberger
1557-1565
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes

PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes

https://doi.org/10.18632/oncotarget.716

Filip Janku, Jennifer J. Wheler, Aung Naing, Vanda M. T. Stepanek, Gerald S. Falchook, Siqing Fu, Ignacio Garrido-Laguna, Apostolia M. Tsimberidou, Sarina A. Piha-Paul, Stacy L. Moulder, J. Jack Lee, Rajyalakshmi Luthra, David S. Hong,  and Razelle Kurzrock
1566-1575
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

FAK is a critical regulator of neuroblastoma liver metastasis

FAK is a critical regulator of neuroblastoma liver metastasis

https://doi.org/10.18632/oncotarget.732

Sora Lee, Jingbo Qiao, Pritha Paul, Kathleen L. O’Connor, Mark Evers,  and Dai H. Chung
1576-1587
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML)

Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML)

https://doi.org/10.18632/oncotarget.733

Harald Herrmann, Katharina Blatt, Junwei Shi, Karoline V. Gleixner, Sabine Cerny-Reiterer, Leonhard Müllauer, Christopher R. Vakoc, Wolfgang R. Sperr, Hans-Peter Horny, James E. Bradner, Johannes Zuber,  and Peter Valent
1588-1599
Abstract  |  PDF  |  HTML  |  Order a Reprint

Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: Utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment

Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: Utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment

https://doi.org/10.18632/oncotarget.742

Sílvia Cufí, Alejandro Vazquez-Martin, Ceistina Oliveras-Ferraros, Bruna Corominas-Faja, Ander Urruticoechea, Begoña Martin-Castillo,  and Javier A Menendez
1600-1614
Abstract  |  PDF  |  HTML  |  Order a Reprint

A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia

A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia

https://doi.org/10.18632/oncotarget.762

Francesca Chiarini, Annalisa Lonetti, Gabriella Teti, Ester Orsini, Daniela Bressanin, Alessandra Cappellini, Francesca Ricci, Pier Luigi Tazzari, Andrea Ognibene, Mirella Falconi, Pasqualepaolo Pagliaro, Ilaria Iacobucci, Giovanni Martinelli, Sergio Amadori, James A McCubrey,  and Alberto M Martelli
1615-1628
Abstract  |  PDF  |  HTML  |  Order a Reprint

Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer

Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer

https://doi.org/10.18632/oncotarget.790

Suyoun Chung, Hanae Suzuki, Takashi Miyamoto, Naofumi Takamatsu, Ayako Tatsuguchi, Koji Ueda, Kyoko Kijima, Yusuke Nakamura,  and Yo Matsuo
1629-1640
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

Lin28b Promotes Head and Neck Cancer Progression via Modulation of the Insulin-Like Growth Factor Survival Pathway

Lin28b Promotes Head and Neck Cancer Progression via Modulation of the Insulin-Like Growth Factor Survival Pathway

https://doi.org/10.18632/oncotarget.785

Nehad M Alajez, Wei Shi, Dennis Wong, Michelle Lenarduzzi, John Waldron, Ilan Weinreb,  and Fei-Fei Liu
1641-1652
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

Stress Response of Glioblastoma Cells Mediated by miR-17-5p Targeting PTEN and the Passenger Strand miR-17-3p Targeting MDM2

Stress Response of Glioblastoma Cells Mediated by miR-17-5p Targeting PTEN and the Passenger Strand miR-17-3p Targeting MDM2

https://doi.org/10.18632/oncotarget.810

Haoran Li,  and Burton B Yang
1653-1668
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia

STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia

https://doi.org/10.18632/oncotarget.806

Wolfgang Warsch, Eva Grundschober, Angelika Berger, Lars Gille, Sabine Cerny-Reiterer, Anca-Sarmiza Tigan, Andrea Hoelbl-Kovacic, Peter Valent, Richard Moriggl,  and Veronika Sexl
1669-1687
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

Simalikalactone E (SkE), a new weapon in the armamentarium of drugs targeting cancers that exhibit constitutive activation of the ERK pathway

Simalikalactone E (SkE), a new weapon in the armamentarium of drugs targeting cancers that exhibit constitutive activation of the ERK pathway

https://doi.org/10.18632/oncotarget.791

Guillaume Robert, Valérie Jullian, Arnaud Jacquel, Clémence Ginet, Maeva Dufies, Stephanie Torino, Anaïs Pottier, Frederic Peyrade, Sophie Tartare-Deckert, Geneviève Bourdy, Eric Deharo,  and Patrick Auberger
1688-1699
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

Gene expression-based risk score in diffuse large B-cell lymphoma

Gene expression-based risk score in diffuse large B-cell lymphoma

https://doi.org/10.18632/oncotarget.807

Caroline Bret, Bernard Klein,  and Jérôme Moreaux
1700-1710
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

Research Perspectives

Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI’s provocative questions

Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI’s provocative questions

https://doi.org/10.18632/oncotarget.890

Mikhail V. Blagosklonny
1711-1724
Abstract  |  PDF  |  HTML  |  Order a Reprint


Copyright © 2017 Impact Journals
Impact Journals is a registered trademark of Impact Journals, LLC